TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00077922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-2
Description: 40 micrograms/kg every other day (QOD) x 3 every 4 weeks
Study: NCT04917250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/㎡，d1,4 ivdrip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500IU/㎡, maximum dose less than 3750IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/㎡，d1-3 ivdrip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg/d d1-4 ivdrip
Study: NCT04606407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungFit™
Description: Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
Study: NCT02804373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin (OXT) continuous
Description: Administration of 24 IU of oxytocin daily during 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo daily during 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo continuous
Description: Placebo administration the following 2 days after each OXT administration, during 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Administration of 24 IU of oxytocin every 3 days during 28 days.
Study: NCT00626769

Intervention type: DIETARY_SUPPLEMENT
Intervention: aglycone genistein
Description: 2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.

Intervention type: DIETARY_SUPPLEMENT
Intervention: placebo
Description: 2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
Study: NCT02335983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
Study: NCT03560986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 100 mg
Description: 100 mg neridronic acid supplied in glass vials in 8 mL of excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glass vials with matching placebo.
Study: NCT05015322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: 5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: 5 mL of 0.25% bupivacaine containing 20 mg methylprednisolone was administered to the subacromial area for the subacromial+acromioclavicular joint injection. In addition, 2 mL of 20 mg methylprednisolone and the same concentration of local anaesthetic were injected into the acromioclavicular joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine and methylprednisolone
Description: suprascapular nerve block was administered with a mixture of 10 mL of 0.25% bupivacaine and 40 mg methylprednisolone
Study: NCT01956058

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy remedial
Description: brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
Study: NCT02642848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HTO with microfracture
Description: High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HTO with microfracture
Description: High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO with microfracture
Description: High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of bone marrow stem cell
Description: Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of adipose derived stem cell
Description: Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
Study: NCT04142957

Intervention type: OTHER
Intervention: COPD Pal
Description: 'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
Study: NCT03121287

Intervention type: OTHER
Intervention: Imaging Biomarkers
Description: Whole lung volumetric CT scans
Study: NCT03767855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Granules in Capsule
Description: CK-3773274 formulated as granules in capsule
Study: NCT02077491

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-protein diet and resistance training
Description: The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
Study: NCT02668172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: as mono-therapy or in combination with pegvisomant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: as mono-therapy or in combination with pegvisomant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: as mono-therapy or in combination with pegvisomant
Study: NCT03121287

Intervention type: OTHER
Intervention: Pulmonary
Description: Pulmonary Function Tests \& 6 minute hall walk
Study: NCT02668172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: only in combination with pasireotide LAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: only in combination with pasireotide LAR
Study: NCT03121807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oliclinomel N4 Per bag 1.5 L
Description: Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT00047853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock device
Description: A participant could receive a shock or not receive as shock

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock device
Description: A participant could receive a shock or not receive as shock

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic startle
Description: Acoustic startle for MEG only
Study: NCT03438760

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Science + Phonological Awareness
Description: The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science + Grammar Intervention
Description: The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science + Vocabulary Intervention
Description: The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
Study: NCT01091142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
Study: NCT04616924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHB-204
Description: RHB-204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to RHB-204
Study: NCT03234270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Core temperature measurements
Description: Core temperature measurements with coretemp pill

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core temperature measurements
Description: Core temperature measurements with coretemp pill
Study: NCT01688999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
Study: NCT02768103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task-based training
Description: The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
Study: NCT01787955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPPD with Braun anastomosis
Description: making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PPPD
Study: NCT03121287

Intervention type: OTHER
Intervention: Imaging
Description: Cardiac MRI

Intervention type: OTHER
Intervention: Specimen Collection
Description: Blood draw
Study: NCT03272061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise program
Description: Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
Study: NCT03562520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change counseling
Description: Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers.
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
Study: NCT01716624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: standard oral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A injection
Description: 10 units/kg injected into the detrusor muscle using cystoscopy
Study: NCT00619112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: single arm study
Study: NCT00986518

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adaptive autologous cell immunotherapy
Description: each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
Study: NCT03882528

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum malaria parasite
Description: Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
Study: NCT01140555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GYNECARE GYNOCCLUDE™
Description: GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
Study: NCT02041910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: MSCs injection intratesticular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: 60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
Study: NCT03778658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants will engage in a multimodal aerobic and strength training intervention.
Study: NCT03155386

Intervention type: OTHER
Intervention: Angiommamography
Description: A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
Study: NCT03895385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
Study: NCT03767855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Granules in Capsule
Description: CK-3773274 formulated as granules in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Granules in Capsule
Description: CK-3773274 formulated as granules in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Granules in Capsule
Description: CK-3773274 formulated as granules in capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Granules in Capsule
Description: Placebo formulated as granules in capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Granules in Capsule
Description: Placebo formulated as granules in capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Granules in Capsule
Description: Placebo formulated as granules in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Tablets
Description: CK-3773274 formulated as tablets
Study: NCT04166773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02908477

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy
Description: 60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Radiation Therapy
Description: 60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 15 mg/m2. Experimental arm only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 40 mg/m2. Standard arm only.
Study: NCT03159702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evomela
Description: 140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of \>3
Study: NCT02951455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building Project
Description: Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building Project
Description: Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
Study: NCT03279497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health game
Description: Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sport and fitness application
Description: Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
Study: NCT01730066

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. plantarum 299 and L. plantarum 299v (+maltodextrin)
Description: Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups
Study: NCT02078336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Mylan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam Mylan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Study: NCT00725205

Intervention type: BIOLOGICAL
Intervention: PegIntron (Peginterferon alfa-2b)
Description: Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.

Intervention type: DRUG
Intervention: Rebetol (Ribavirin)
Description: Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.